כנס "טיפול באנשים טרנסג'נדרים" 2019

טיפול באנשים טרנסג'נדרים

כנס רופאי ורופאות משפחה בנושא טיפול באנשים טרנסג'נדרים שמתקיים ב11/12/2019, בתה"ש, רמת גן.  מחקרים מהשנים האחרונות מעידים כי כ-0.6% מהאוכלוסייה מזדהים כאנשים על הספקטרום הטרנסג'נדרי, כאשר שיעור זה נמצא במגמת עלייה בשנים האחרונות ובקרב נוער מגיע גם ל 2-3%.

יש רופא על הבר?

יש רופא על הבר? רופאי איכילוב באים לדבר על בריאות וחדשנות רפואית

זו השנה השלישית שמיזם "יש רופא על הבר?" יוצא אל הדרך ומעניק לכם הזדמנות להיחשף לדברים הכי מעניינים שקורים היום בעולם הרפואה, תוך כדי צריכה (מבוקרת – בכל זאת רופאים) של אלכוהול.

הרצאה בכנס אנדוקריני ישראלי – IES – 3/2017

Anti-Mullerian Hormone serum levels remain stable under cross-sex hormone therapy of transgender men Iris Yaish1 , Iris Yaish1 , Gustavo Melinger2 , Yael Sofer1 , Nechama Golani1 , Marianna Yaron1 , Dana Zaid1 , Foad Azem2 , Naftali Stern1 , Yona Greenman1 1 Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Israel 2 Lis Maternity Hospital, Tel Aviv-Sourasky Medical Center, Israel Background: Although successful pregnancies carried by transgender men have been reported, long-term effects of testosterone therapy on fertility remain unknown. Aims: To study markers of ovarian reserve during testosterone therapy Methods: Prospective open-label study of transgender men prior and during treatment with IM Testoviron Depot 250 mg q3 weeks. Sampling was conducted in the follicular phase at baseline and 10 days following the testosterone injection three and 12 months subsequently. Main outcome measures: AMH serum levels; endometrial thickness and antral follicular count determined by pelvic US. Results: Thirty five subjects (mean age 24±5.9 y) were included. Preliminary results of twenty two patients with at least one follow up visit are reported. AMH levels were within the normal range (5.8±2.9 ng/ml) and did not change significantly after three (5.3±2.4 ng/ml, N=22) and 12 months of treatment (4±2.2 ng/ml, N=8). As expected, testosterone levels increased (0.57 ± 0.7, 6 ±3.2 ,6.6 ±2.8 ng/ml; p0.0001) and estradiol levels decreased (187±184 , 57±15, 54.8 pg/ml; p=0.012) after three and 12 months respectively. There was a modest but significant decrease in LH levels (7.7±5, 4.2±3.4, 3.9 ± 2.8 mIU/ml, p=0.022), but FSH levels (4.1±1.7, 4.4±2.2, 4.7±1.8 mIU/ml), as well as endometrial thickness (7.2±3.9, 5.3±1.2, 5±3.3 mm) remained unchanged. In all but two studies, multiple ovarian small follicles were detected by pelvic sonography. Conclusion: AMH levels remain stable during short term testosterone treatment. Further, there is no suppression of the hypothalamo-pituitary-gonadal axis and ovarian folliculogenesis is maintained. Longer follow up is needed for assessment of testosterone effects on fertility potential.

הרצאה בכנס האנדוקריני הישראלי – IES, במרץ 2017 – לתוכנית המלאה של הכנס – לחץ כאן. הצגת מחקר בנושא: Anti-Mullerian Hormone serum levels remain stable under cross-sex hormone therapy of transgender men Iris Yaish1 , Iris Yaish1 , Gustavo Melinger2 , Yael Sofer1 , Nechama Golani1 , Marianna Yaron1 , Dana Zaid1 , Foad Azem2 […]

Endocrine Society

The Effect of Radioactive Iodine 131I Treatment on Ovarian Reserve : Preliminary Data from a Prospective Study Iris Yaish, Foad Azem, Rona Limor, Sivan Shamai, Naftali Stern, Orit Gutfeld, Karen Michele Tordjman and Etty Osher Abstract: Background and aim of study: Differentiated thyroid carcinoma and thyrotoxicosis are commonly diagnosed in women in their reproductive years. In […]

נא הזינו את פרטיכם
במערכת לקביעת תורים